Retatrutide, by Soma Corp., is attracting significant attention as a novel treatment for obesity management . This dual-action medication merges the mechanism of a GLP-1 receptor activator and a GIP receptor activator , aiming to effectively promote weight loss but also target associated metabolic issues . Early patient studies have indicated impre